MYND-604

**MYND-604** is an oral dosage form of psilocybin being developed by MYND Life Sciences for the treatment of **major depressive disorder (MDD)**, particularly inflammation-triggered forms linked to gut microbiome dysregulation. It leverages psilocybin's anti-inflammatory properties to modulate the **human mycogene** and microbiota-gut-brain axis, aiming to dampen inflammatory responses associated with MDD. The program is in preclinical development, with provisional patents filed, and involves research at the University of British Columbia under Dr. Wilfred Jefferies, focusing on lead analog identification, dosing, toxicity, and IND-enabling studies for clinical trials.[1][2][3][5][7][8]